When was Treeline Biosciences founded?

Treeline Biosciences was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Treeline Biosciences located?

Treeline Biosciences is headquartered in Stamford, United States.

Who is the current CEO of Treeline Biosciences?

Joshua Bilenker of Treeline Biosciences. They have also founded 1 company.

How many employees does Treeline Biosciences have?

As of Sep 30, 2026, the latest employee count at Treeline Biosciences is 174.

Is Treeline Biosciences a funded company?

Treeline Biosciences is a funded company, having raised a total of $1.1B across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 09, 2021.

When was the latest funding round of Treeline Biosciences?

Treeline Biosciences' latest funding was a $***** Series A round on Aug 21, 2025, with participation from 11 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $6.54B in funding in 2026 to date.

Where does Treeline Biosciences rank among its competitors?

Treeline Biosciences ranks 158th amongst 3422 active competitors, of which 1129 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Treeline Biosciences?

Treeline Biosciences' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Treeline Biosciences - 2026 Company Profile, Team, Funding & Competitors

Treeline Biosciences is a series A company based in Stamford (United States), founded in 2021 by Jeffrey Engelman and Joshua Bilenker. It operates as a Developer of transformative precision medicines to treat cancer. Treeline Biosciences has raised $1.1B in funding from KKR and Arch Venture Partners. The company has 3422 active competitors, including 1129 funded and 787 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of transformative precision medicines to treat cancer. The company's drug discovery platform includes mechanistic biology, medicinal chemistry, computational science, structural biology & protein science.

Website: treeline.bio
Email ID: *****@treeline.bio

Key Metrics

Founded Year

2021

Location

Stamford, United States

Stage

Series A

Total Funding

$1.1B in 4 rounds

Latest Funding Round

Series A, Aug 21, 2025, $*****

Investors

KKR & 10 more

Ranked

158^th among 3422 active competitors

Employee Count

174 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3029 more

View Treeline Biosciences' full profile

Treeline Biosciences has raised a total funding of $1.1B over 4 rounds. Its first funding round was on Apr 09, 2021. Its latest funding round was a Series A round on Aug 21, 2025 for $*****. 11 investors participated in its latest round. Treeline Biosciences has 11 institutional investors.

Here is the list of recent funding rounds of Treeline Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 21, 2025	7915092	Series A	2718092	8460491	5081601	6492529
Oct 02, 2024	4103288	Series A	7655603	5127851	1407456	8319067
Sep 26, 2022	3660528	Series A	8582360	3851475	KKR	4564228

Access funding benchmarks and valuations. Sign up today!

View details of Treeline Biosciences's funding rounds and investors

The founders of Treeline Biosciences are Jeffrey Engelman and Joshua Bilenker. Joshua Bilenker is the CEO of Treeline Biosciences.

Here are the details of Treeline Biosciences' key team members:

Jeffrey Engelman: Co-Founder of Treeline Biosciences.
Joshua Bilenker: Co-Founder & CEO of Treeline Biosciences.

View details of Treeline Biosciences's Founder profiles and Board Members

Treeline Biosciences' employee count trend

Treeline Biosciences has 174 employees as of Sep 26. Here is Treeline Biosciences's employee count trend over the years:

Employee count trend for Treeline Biosciences

Uncover Treeline Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Treeline Biosciences include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Treeline Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
158th	Treeline Biosciences 2021, Stamford (United States), Series A	Developer of transformative precision medicines to treat cancer	$1.1B	Access Industries, Fidelity Investments & 9 others	60/100